[68Ga]Ga-FAPI-04 PET与[18F]FDG PET在原发性胃肠道肿瘤及转移评估中的头对头比较:系统评价与Meta分析
该系统评价与Meta分析纳入16项头对头比较研究、共597例患者,比较[68Ga]Ga-FAPI-04 PET与[18F]FDG PET对原发性胃肠道肿瘤及转移的诊断效能;结果显示[68Ga]Ga-FAPI-04 PET在原发性肿瘤、转移性淋巴结、远处转移及腹膜转移的敏感度上均优于[18F]FDG,在胃原发肿瘤和转移性淋巴结的特异度上也更优,作者认为其比[18F]FDG PET更适合诊断印戒细胞癌。
要点
- 胃肠道肿瘤中,[68Ga]Ga-FAPI-04 PET对原发肿瘤的合并敏感度0.99(95%CI 0.95-1.00)优于[18F]FDG的0.82(95%CI 0.67-0.91)。
- 对转移性淋巴结,[68Ga]Ga-FAPI-04 PET合并敏感度0.95(95%CI 0.81-0.99)优于[18F]FDG的0.56(95%CI 0.43-0.69)。
- 胃印戒细胞癌中,[68Ga]Ga-FAPI-04 PET敏感度0.99(95%CI 0.19-1.00),[18F]FDG PET敏感度0.46。
核心结论
- [68Ga]Ga-FAPI-04 PET在原发性胃肠道肿瘤及转移的诊断中,敏感度和特异度均优于[18F]FDG PET;作者认为其比[18F]FDG PET更适合诊断印戒细胞癌。
研究设计与样本
- 系统评价与Meta分析,系统检索PubMed、Embase、Web of Science和Cochrane Library数据库至2024年4月16日,纳入16项头对头比较研究,共597例患者(男性384例),其中9项为胃癌、4项为结直肠癌、3项为包括胃、十二指肠、阑尾和结直肠癌在内的多种胃肠道肿瘤,采用QUADAS-2评估纳入文献质量。
诊断标准与关键数值
- 胃癌原发肿瘤:[68Ga]Ga-FAPI-04 PET敏感度0.98、特异度0.93,[18F]FDG PET敏感度0.74、特异度0.48。
- 胃癌淋巴结转移:[68Ga]Ga-FAPI-04 PET敏感度0.90、特异度0.93,[18F]FDG PET敏感度0.45、特异度0.83。
- 胃印戒细胞癌:[68Ga]Ga-FAPI-04 PET敏感度0.99(95%CI 0.19-1.00),[18F]FDG PET敏感度0.46;两者SUVmax平均差为5.75(95%CI 1.42-10.08)。
- 结直肠癌原发肿瘤:[68Ga]Ga-FAPI-04 PET敏感度1.00,[18F]FDG PET敏感度0.97。
- 胃肠道肿瘤总体:原发肿瘤合并敏感度[68Ga]Ga-FAPI-04 PET 0.99(95%CI 0.95-1.00)vs [18F]FDG PET 0.82(95%CI 0.67-0.91),合并特异度0.90 vs 0.74;转移性淋巴结合并敏感度0.95(95%CI 0.81-0.99)vs 0.56(95%CI 0.43-0.69),合并特异度0.89 vs 0.84;远处转移敏感度0.93 vs 0.63;腹膜转移敏感度0.99 vs 0.51。
临床应用与阅片要点
- 作者认为[68Ga]Ga-FAPI-04 PET比[18F]FDG PET更适合诊断印戒细胞癌。
- [68Ga]Ga-FAPI-04 PET对原发性胃肠道肿瘤及转移的SUVmax和TBR优于[18F]FDG PET。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: Gastrointestinal cancers pose a major public health challenge due to very aggressive malignancy, the quick and widespread metastases, relapse frequently in lymph node and omentum, and poor prognosis. [68Ga]Ga-FAPI-04 PET is widely used to diagnose gastrointestinal tumors. This study aimed to conduct a head-to-head comparison of the [68Ga]Ga-FAPI-04 and [18F]-FDG imaging methods for diagnosing primary gastrointestinal tumors and metastases.
METHODS: The PubMed, Embase, Web of Science, and Cochrane Library databases were systematically searched up to 16 April 2024. The included studies involved head-to-head comparisons to evaluate [68Ga]Ga-FAPI-04 and [18F]FDG PET in gastrointestinal cancers. QUADAS-2 was used to assess the quality of the included articles.
RESULTS: The study included 16 studies. Nine studies were performed on gastric cancer, four on colorectal cancer, and the remaining three studies of various gastrointestinal tumors, including gastric, duodenal, appendiceal and colorectal cancers. The total number of patients was 597, including 384 males. In gastric cancer, [68Ga]Ga-FAPI-04 PET demonstrated superior sensitivity for the primary tumors (0.98 vs. 0.74) and lymph node metastases (0.90 vs. 0.45) than [18F]FDG. In gastric cancer, [68Ga]Ga-FAPI-04 PET demonstrated superior specificity for the primary tumors (0.93 vs. 0.48) and lymph node metastases (0.93 vs. 0.83) than [18F]FDG. [68Ga]Ga-FAPI-04 PET had a sensitivity of 0.99 (95% CI 0.19-1.00) for gastric signet-ring-cell carcinoma (GSRCC), and [18F]FDG PET had a sensitivity of 0.46 for GSRCC. There was a significant difference in mean difference (MD) of SUVmax (MD 5.75 [95% CI 1.42-10.08]) for GSRCC between [68Ga]Ga-FAPI-04 and [18F]FDG. In colorectal cancer, [68Ga]Ga-FAPI-04 PET was more sensitive for primary tumors (1.00 vs. 0.97). In gastrointestinal cancers, [68Ga]Ga-FAPI-04 PET showed superior pooled sensitivity compared with [18F]FDG for primary tumors (0.99 [95% CI 0.95-1.00] vs. 0.82 [95% CI 0.67-0.91]), metastatic lymph nodes (0.95 [95% CI 0.81-0.99] vs. 0.56 [95% CI 0.43-0.69]), distant metastases (0.93 vs. 0.63), and peritoneal metastases (0.99 vs. 0.51). In gastrointestinal cancers, [68Ga]Ga-FAPI-04 PET showed superior pooled specificity compared with [18F]FDG for primary tumors (0.90 vs. 0.74), and metastatic lymph nodes (0.89 vs. 0.84). Furthermore, [68Ga]Ga-FAPI-04 had a superior SUVmax and TBR compared with [18F]FDG for primary gastrointestinal tumors and metastases.
CONCLUSION: [68Ga]Ga-FAPI-04 PET demonstrated superior sensitivity and specificity in primary gastrointestinal cancers and metastases in comparison with [18F]FDG. The results demonstrated that [68Ga]Ga-FAPI-04 PET was a more suitable modality than [18F]FDG PET for the diagnosis of SRCC.
引用
- Zhao Y, Wang S, Du B, et al. Head-to-head Comparison of [68Ga]Ga-FAPI-04 PET and [18F]FDG PET in the Evaluation of Primary Gastrointestinal Tumors and Metastases: A Systematic Review and Meta-analysis. Acad Radiol. 2025. PMID: 40506350. doi:10.1016/j.acra.2025.05.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。